NR1H3 and Hepatic steatosis: ORO staining indicated that LXRα antagonist treatment significantly repressed olanzapine-induced lipid accumulation in HepG2 cells and AML12 cells (Fig. 4J), whereas LXRα overexpression exacerbated hepatic steatosis (Fig. 4G).